Statins for primary prevention: Identifying low-risk individuals

Nature Reviews Cardiology

Volumn 10, Issue 9, 2013, Pages 547-

  Huang, Yu Li ^a   Huang, Yi ^b   Wu, Yan Xian ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ALGORITHM; CARDIOVASCULAR RISK; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; FRAMINGHAM RISK SCORE; HUMAN; ISCHEMIC HEART DISEASE; LETTER; LOW RISK POPULATION; META ANALYSIS (TOPIC); PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY OF LIFE; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; PROCEDURES; CARDIOVASCULAR DISEASE; DYSLIPIDEMIA; METHODOLOGY; NOTE;

CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRIMARY PREVENTION;

EID: 84883147860     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2013.80-c1     Document Type: Letter

References (11)

1. Reiner, Z. Statins in the primary prevention of cardiovascular disease. Nat. Rev. Cardiol. http://dx.doi.org/10.1038/nrcardio.2013.80.
2. Smeeth, L. & Hemingway, H. Improving vascular health: are pills the answer? BMJ 344, e3802 (2012).
3. Mihaylova, B. et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380, 581-590 (2012).
4. Madanieh, R., Hasan, R. K., Anusionwu, O. F., Blumenthal, R. S. & Blaha, M. J. Cardiovascular disease prevention: matching evidence-based algorithms with individualized care. Clin. Pharmacol. Ther. 93, 321-323 (2013).
5. Ebrahim, S. & Casas, J. P. Statins for all by the age of 50 years? Lancet 380, 545-547 (2012).
6. Taylor, F. et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews Issue 1. Art. No.: CD004816. http://dx.doi.org/10.1002/14651858.CD004816.pub4.
7. Ridker, P. M. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195-2207 (2008).
8. Lakoski, S. G. et al. Coronary artery calcium scores and risk for cardiovascular events in women classified as "low risk" based on Framingham risk score: the multi-ethnic study of atherosclerosis (MESA). Arch. Intern. Med. 167, 2437-2442 (2007).
9. Kondos, G. T. et al. Electron-beam tomography coronary artery calcium and cardiac events: a 37-month follow-up of 5635 initially asymptomatic low- to intermediate-risk adults. Circulation 107, 2571-2576 (2003).
10. Blaha, M. J. et al. Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study. Lancet 378, 684-692 (2011).
11. Arad, Y., Spadaro, L. A., Roth, M., Newstein, D. & Guerci, A. D. Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial. J. Am. Coll. Cardiol. 46, 166-172 (2005).